FDA Approves Ozempic to Treat Kidney Disease

The food and medication administration approved an Oskempic to reduce the risk of kidney disease.

On Tuesday, January 28, the agency announced that the drug can now be used to reduce the risk of kidney failure and the progression of the disease, as well as death due to cardiovascular disease, in adults with type 2 diabetes and chronic kidney disease.

Orempic is already widely used and the first FDA has been approved in 2017 to treat type 2 diabetes – take weekly injection into your thigh, stomach or hand – is a semaglutide brand, which acts in the brain to influence satiat.

The new FDA approval is the drug to the first treatment option for GLP-1 for people with type 2 diabetes and chronic kidney disease.

“Chronic kidney disease is very serious and common in patients living with type 2 diabetes and is a critical need for adults living with these chamberbits,” said Anna Windle – Senior Vice President of Clinical Development, Medical and Regulatory Affairs for Novi Nordisk, Oskempic Manufacturer -In a statement to the public. “This Oskempic approval allows us to spread the conditions within the cardiovascular-kidney-metabolic syndrome, which affect millions of adults and may have serious consequences if it is not treated.”

Orempic and similar drugs can offer health benefits after weight loss, including reduced craving for alcohol

Orempic injector.

Getty

Never miss the story -son for a daily newsletter of people to be up to date with the best of what people can offer, from news of glorious to convincing stories of human interest.

See also  Carrie Preston on the 'Old Adage' That Became a Mantra in Her 25-Year Marriage to Lost's Michael Emerson (Exclusive)

The decision was made after a clinical trial with more than 3,500 people, where researchers found that medication weekly injections reduce the risk of kidney disease by 24% in people who had diabetes.

In addition, the risk of heart disease in adults in type 2 diabetes and chronic kidney disease is reduced by about 5%.

“From my point of view as a doctor, you don’t get [diabetes, obesity, chronic kidney disease and cardiovascular disease] Insulation, “CNBC Stephen Gough, a global medical director of Novi Nordiska, told CNBC.” Unfortunately, these diseases are compliant. They gather within the same individuals. So, if you have a medicine that can target each of these morabids in one injection, then deal with what is actually important to the patient. ”

Categories: Trends
Source: HIS Education

Rate this post

Leave a Comment